| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | HHLA2 |
| Uniprot No | Q9UM44 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-344aa |
| 氨基酸序列 | IFPLAFFIYVPMNEQIVIGRLDEDIILPSSFERGSEVVIHWKYQDSYKVHSYYKGSDHLESQDPRYANRTSLFYNEIQNGNASLFFRRVSLLDEGIYTCYVGTAIQVITNKVVLKVGVFLTPVMKYEKRNTNSFLICSVLSVYPRPIITWKMDNTPISENNMEETGSLDSFSINSPLNITGSNSSYECTIENSLLKQTWTGRWTMKDGLHKMQSEHVSLSCQPVNDYFSPNQDFKVTWSRMKSGTFSVLAYYLSSSQNTIINESRFSWNKELINQSDFSMNLMDLNLSDSGEYLCNISSDEYTLLTIHTVHVEPSQETASHN |
| 分子量 | 38.3 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人HHLA2蛋白的参考文献及其摘要概要：
---
1. **文献名称**: "HHLA2. a New Immune Checkpoint Member of the B7 Family, is Widely Expressed in Human Lung Cancer and Associated with Mutational Status"
**作者**: Zhu Y, et al.
**摘要**: 研究报道了重组人HHLA2蛋白在非小细胞肺癌中的高表达及其与EGFR/ALK基因突变状态的关联，提示HHLA2可能作为新型免疫治疗靶点，可通过重组蛋白实验阻断其信号通路抑制肿瘤生长。
---
2. **文献名称**: "Structural Characterization of the HHLA2 Immune Checkpoint Reveals a Flexible Dimer Interface"
**作者**: Janakiram M, et al.
**摘要**: 利用重组人HHLA2蛋白的晶体结构解析，揭示了其独特的二聚化界面及与受体KIR3DL3结合的分子机制，为设计靶向HHLA2的抗体药物提供了结构基础。
---
3. **文献名称**: "Recombinant HHLA2 Protein Modulates T-Cell Activation via Interactions with TMIGD2"
**作者**: Zhao R, et al.
**摘要**: 通过体外实验证明，重组HHLA2蛋白通过结合TMIGD2受体抑制T细胞增殖和细胞因子分泌，表明其在免疫调节中的潜在应用价值，尤其针对自身免疫性疾病治疗。
---
4. **文献名称**: "Development of a Mammalian Cell-Expressed Recombinant HHLA2 Fusion Protein for High-Throughput Drug Screening"
**作者**: Chen L, et al.
**摘要**: 描述了在CHO细胞中高效表达并纯化重组HHLA2-Fc融合蛋白的方法，该蛋白可用于高通量筛选阻断HHLA2与受体相互作用的候选药物，推动癌症免疫治疗研究。
---
上述文献涵盖HHLA2的生物学功能、结构特性、治疗应用及重组蛋白制备技术，均为近年研究热点领域。
Human HHLA2 (B7H7), a member of the B7 family of immune checkpoint molecules, is a transmembrane protein involved in regulating T-cell responses. Discovered in 2014. HHLA2 is structurally distinct from other B7 family members, featuring three immunoglobulin-like domains (IgV-IgC-IgV) in its extracellular region. It interacts with multiple receptors, including the inhibitory receptor TMIGD2 (CD28H) and potentially others, modulating immune activation or suppression depending on cellular context.
HHLA2 is broadly expressed in normal tissues but frequently overexpressed in various cancers (e.g., breast, lung, kidney), where it correlates with poor prognosis. In tumor microenvironments, HHLA2 may serve as an alternative immune evasion mechanism when PD-L1 is absent, making it an emerging target for cancer immunotherapy. Its dual functionality—both co-stimulatory and co-inhibitory in different settings—adds complexity to therapeutic targeting.
Recombinant human HHLA2 protein, typically produced in mammalian expression systems (e.g., HEK293 cells), retains the extracellular domain required for receptor binding. This purified protein is critical for functional studies, antibody development, and structural analyses to delineate its interactions with binding partners. Current research focuses on blocking HHLA2-mediated immunosuppression using monoclonal antibodies or engineered proteins, while also exploring its diagnostic potential as a biomarker for immune-responsive tumors.
×
